A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Newron Pharmaceuticals
- 05 Sep 2017 According to results presented at the 30th ECNP Congress, a protocol was amended in terms of ramdomisation from 3:1 to 1:1.
- 25 Mar 2017 Results presented at the 16th International Congress on Schizophrenia Research 2017, according to a Newron Pharmaceuticals media release.
- 25 Mar 2017 Results published in a Newron Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History